
INZY
Inozyme Pharma Inc
- Overview
- Forecast
- Valuation
- Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
279.59M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
61.86M
EV
219.76M
EV/OCF(TTM)
--
P/S(TTM)
--
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The Company is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The Company also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
Show More
8 Analyst Rating

Wall Street analysts forecast INZY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INZY is 7.50 USD with a low forecast of 4.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
6 Hold
0 Sell
Hold

Current: 0

Low
4.00
Averages
7.50
High
16.00

Current: 0

Low
4.00
Averages
7.50
High
16.00
Wells Fargo
Overweight
to
Equal Weight
downgrade
$4
2025-05-16
Reason
Wells Fargo
Price Target
$4
2025-05-16
downgrade
Overweight
to
Equal Weight
Reason
Wells Fargo downgraded Inozyme (INZY) to Equal Weight from Overweight with a $4 price target after BioMarin Pharmaceutical (BMRN) announced a definitive agreement to acquire the company for $4.00 per share in cash.
Needham
Joseph Stringer
Buy -> Hold
downgrade
2025-05-16
Reason
Needham
Joseph Stringer
Price Target
2025-05-16
downgrade
Buy -> Hold
Reason
Needham analyst Joseph Stringer downgraded Inozyme (INZY) to Hold from Buy without a price target after BioMarin Pharmaceutical (BMRN) announced a definitive agreement to acquire the company for $4.00 per share in cash.
Raymond James
Outperform -> Market Perform
downgrade
$4.00
2025-05-16
Reason
Raymond James
Price Target
$4.00
2025-05-16
downgrade
Outperform -> Market Perform
Reason
Raymond James downgraded Inozyme (INZY) to Market Perform from Outperform after BioMarin (BMRN) agreed to acquire Inozyme for $4.00 per share in cash.
Jefferies
Buy -> Hold
downgrade
$15 -> $4
2025-05-16
Reason
Jefferies
Price Target
$15 -> $4
2025-05-16
downgrade
Buy -> Hold
Reason
Jefferies downgraded Inozyme (INZY) to Hold from Buy with a price target of $4, down from $15, after BioMarin Pharmaceutical (BMRN) agreed to acquire the company for $4.00 per share in cash. The firm believes INZ-701 fits into BioMarin's enzyme treatment portfolio as a bolt-on, the analyst tells investors.
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$16
2025-04-10
Reason
HC Wainwright & Co.
Edward White
Price Target
$16
2025-04-10
Reiterates
Strong Buy
Reason
Needham
Joseph Stringer
Strong Buy
Reiterates
$15
2025-04-08
Reason
Needham
Joseph Stringer
Price Target
$15
2025-04-08
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Inozyme Pharma Inc (INZY.O) is -2.94, compared to its 5-year average forward P/E of -3.96. For a more detailed relative valuation and DCF analysis to assess Inozyme Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.96
Current PE
-2.94
Overvalued PE
-1.06
Undervalued PE
-6.87
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.84
Current EV/EBITDA
-2.21
Overvalued EV/EBITDA
0.49
Undervalued EV/EBITDA
-4.17
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+5.93%
-25.79M
Operating Profit
FY2025Q1
YoY :
+20.10%
-28.04M
Net Income after Tax
FY2025Q1
YoY :
+15.79%
-0.44
EPS - Diluted
FY2025Q1
YoY :
+18.67%
-29.15M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
7.8K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
222.3K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
7.8K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
INZY News & Events
Events Timeline
2025-07-22 (ET)
2025-07-22
08:30:11
Sixteen option delistings on July 22nd

2025-05-16 (ET)
2025-05-16
13:26:28
Leerink bullish on BioMarin following Inozyme deal, expects additional BD

2025-05-16
09:29:29
BioMarin says Inozyme deal to strengthen enzyme therapies portfolio

Sign Up For More Events
Sign Up For More Events
News
8.5
07-01NewsfilterBioMarin Announces Completion of Acquisition of Inozyme
7.0
06-12PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, SVT, HLGN on Behalf of Shareholders
7.0
05-27GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders
Sign Up For More News
People Also Watch

GUTS
Fractyl Health Inc
1.920
USD
+0.52%

VOC
VOC Energy Trust
3.290
USD
+2.17%

ENTX
Entera Bio Ltd
1.860
USD
-2.62%

ME
23andMe Holding Co.
0
USD
-27.05%

OSS
One Stop Systems Inc
5.220
USD
-6.12%

IH
Ihuman Inc
2.920
USD
-3.31%

XFOR
X4 Pharmaceuticals Inc
1.820
USD
-0.55%

DBVT
Dbv Technologies SA
9.455
USD
-3.27%

AZI
Autozi Internet Technology (Global) Ltd
0.269
USD
+1.89%

IMAB
I-Mab
2.110
USD
-0.47%
FAQ

What is Inozyme Pharma Inc (INZY) stock price today?
The current price of INZY is 0 USD — it has increased 0.25 % in the last trading day.

What is Inozyme Pharma Inc (INZY)'s business?

What is the price predicton of INZY Stock?

What is Inozyme Pharma Inc (INZY)'s revenue for the last quarter?

What is Inozyme Pharma Inc (INZY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Inozyme Pharma Inc (INZY)'s fundamentals?

How many employees does Inozyme Pharma Inc (INZY). have?
